147 related articles for article (PubMed ID: 23066177)
1. Cartilage targeted chemical delivery of naproxen and ibuprofen for the treatment of arthritis.
Pawar V; Gohil V; Tamboli R; Giridhar R; Yadav MR
J Pharm Bioallied Sci; 2012 Mar; 4(Suppl 1):S10-1. PubMed ID: 23066177
[TBL] [Abstract][Full Text] [Related]
2. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.
Goldenberg MM
Clin Ther; 1999 Sep; 21(9):1497-513; discussion 1427-8. PubMed ID: 10509845
[TBL] [Abstract][Full Text] [Related]
3. Ibuprofen: pharmacology, efficacy and safety.
Rainsford KD
Inflammopharmacology; 2009 Dec; 17(6):275-342. PubMed ID: 19949916
[TBL] [Abstract][Full Text] [Related]
4. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
[TBL] [Abstract][Full Text] [Related]
6. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
Rabeneck L; Goldstein JL; Vu A; Mayne TJ; Rublee DA
Am J Gastroenterol; 2005 May; 100(5):1043-50. PubMed ID: 15842577
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
8. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide-releasing NSAIDs: a review of their current status.
Fiorucci S; Antonelli E; Burgaud JL; Morelli A
Drug Saf; 2001; 24(11):801-11. PubMed ID: 11665868
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
Huang WF; Hsiao FY; Wen YW; Tsai YW
Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of anti-inflammatory and ulcerogenic potential of zinc-ibuprofen and zinc-naproxen complexes in rats.
Jarosz M; Szkaradek N; Marona H; Nowak G; Młyniec K; Librowski T
Inflammopharmacology; 2017 Dec; 25(6):653-663. PubMed ID: 28536986
[TBL] [Abstract][Full Text] [Related]
12. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
Matheson AJ; Figgitt DP
Drugs; 2001; 61(6):833-65. PubMed ID: 11398914
[TBL] [Abstract][Full Text] [Related]
13. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
14. A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis.
Fendrick AM; Greenberg BP
Osteopath Med Prim Care; 2009 Jan; 3():1. PubMed ID: 19126235
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.
Clemett D; Goa KL
Drugs; 2000 Apr; 59(4):957-80. PubMed ID: 10804043
[TBL] [Abstract][Full Text] [Related]
16. Pattern recognition analysis for the prediction of adverse effects by nonsteroidal anti-inflammatory drugs using 1H NMR-based metabolomics in rats.
Um SY; Chung MW; Kim KB; Kim SH; Oh JS; Oh HY; Lee HJ; Choi KH
Anal Chem; 2009 Jun; 81(12):4734-41. PubMed ID: 19462990
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
Lister BJ; Poland M; DeLapp RE
Am J Med; 1993 Aug; 95(2A):2S-9S. PubMed ID: 8356999
[TBL] [Abstract][Full Text] [Related]
18. Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells.
Andrews J; Djakiew D; Krygier S; Andrews P
Cancer Chemother Pharmacol; 2002 Oct; 50(4):277-84. PubMed ID: 12357301
[TBL] [Abstract][Full Text] [Related]
19. Valdecoxib: a review.
Chavez ML; DeKorte CJ
Clin Ther; 2003 Mar; 25(3):817-51. PubMed ID: 12852704
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
